Full TitleA Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
Some non-small cell lung cancers (NSCLC) are driven by alterations in a gene called MET. The purpose of this study is to assess the safety and effectiveness of an investigational drug called REGN5093 in patients with inoperable or metastatic NSCLC that persists despite prior treatment and has MET alterations.
REGN5093 is an antibody like those made by the immune system to identify and attack cancer cells, fight infections, and defend against other harmful cells that come from outside the body. Researchers think that the MET alteration may cause tumors to grow more quickly. REGN5093 was made in a laboratory to bind to the MET protein to block this effect. It is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable or metastatic NSCLC that persists despite prior treatment and has MET alterations.
- Patients should recover from the serious side effects of prior therapies before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alexander Drilon at 646-497-9163.